Over $3.5million Raised for Local Charities at the 30th Annual Scotiabank Toronto Waterfront Marathon
Trevor Hofbauer and Dayna Pidhoresky receive automatic pre-selection for Tokyo 2020 at the 2019 Scotiabank Toronto Waterfront Marathon
TORONTO, Oct. 20, 2019 /CNW/ - More than 26,000 people, from over 70 countries, took part in the 30th annual Scotiabank Toronto Waterfront Marathon this weekend, raising over $3.5 million for 190 charities, through the Scotiabank Charity Challenge.
Race highlights include:
Trevor Hofbauer and Dayna Pidhoresky were the top Canadians in the marathon distance, winning automatic pre-selection for Tokyo 2020 next August.
Kenya's Philemon Rono won the men's marathon, breaking the Canadian All-comers record, finishing in a time of 2:05:00.
Despite travel challenges, Kenya's Magdelyne Masai arrived in time to break the Canadian All-comers record, in a time of 2:22:16.
Filex Chemonges eclipsed the Ugandan National record, previously held by Stephen Kiprotich, set in 2015.
"We had a remarkable day to celebrate the 30th anniversary of the Scotiabank Toronto Waterfront Marathon," says Alan Brookes, Race Director of the Scotiabank Toronto Waterfront Marathon. "Since its inception, we wanted to build a marathon that Toronto and Canada would be proud of and this year, I think the city can take a bow. With the fastest ever marathons run in Canada for both men and women and two Canadians booking their tickets to Tokyo—what a day!"
"We are thrilled with the turnout at this year's Scotiabank Toronto Waterfront Marathon and thank all the runners for joining us and to all of the volunteers who helped make the Marathon such a success," says Mike Tasevski, Vice President of Global Sponsorships at Scotiabank. "We'd also like to thank the runners who have also raised funds for a variety of important charities, through the Scotiabank Charity Challenge. Thanks to them, we're helping many organizations that focus on young people in our community reach their infinite potential, a key priority for Scotiabank."
The Scotiabank Charity Challenge is a turnkey fundraising program that provides a simple and effective way to support local causes that make a big difference in people's lives. Participating charities keep 100 per cent of the proceeds raised, as Scotiabank pays for all transaction and credit card fees.
2019 Scotiabank Toronto Waterfront Marathon Results
#TOwaterfront42K, #ItsYourMoment, #InfinitePotential, and #RunScotia
About the Scotiabank Toronto Waterfront Marathon An IAAF Gold Label race, the Scotiabank Toronto Waterfront Marathon is Canada's premier, big-city running event, the Athletics Canada National Marathon Championships, the Marathon Trials for Tokyo 2020 and the Grand Finale of the 8-race Canada Running Series. In 2018 it attracted more than 25,000 participants from over 70 countries raised $3.5 million for 188 charities through the Scotiabank Charity Challenge and contributed an estimated $28 million to the local economy. The livestream broadcast was watched by more than 54,000 viewers from 146 countries. http://STWM.ca
About Scotiabank At Scotiabank, we aim to support organizations that are committed to helping young people reach their infinite potential. Young people are our future leaders and Scotiabank's goal is to help ensure that they have the necessary skills and resources they need to support their success. Together with our employees, the Bank supports causes at a grassroots level. Recognized as a leader for our charitable donations and philanthropic activities, in 2018, Scotiabank contributed more than $80 million to help our communities around the world.
Scotiabank is Canada's international bank and a leading financial services provider in the Americas. We are dedicated to helping our more than 25 million customers become better off through a broad range of advice, products and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. With a team of more than 100,000 employees and assets of over $1 trillion (as at July 31, 2019), Scotiabank trades on the Toronto Stock Exchange (TSX: BNS) and New York Stock Exchange (NYSE: BNS). For more information, please visit www.scotiabank.com and follow us on Twitter @ScotiabankViews.
SOURCE Scotiabank
Torn Tendon? How to Recover After an Injury
The human body has hundreds of tendons that are susceptible to damage from a trauma injury or from long-term overuse. Amateur and professional athletes or an aging individual is more likely to suffer from a torn tendon injury, and there are a variety of ways to recover from this issue. Here are five ways for you to treat and recover from a damaged tendon.
Elevating the Injured Body Part
Elevating the injured body part can help the blood to circulate better along with preventing any swollen tissues. Experts suggest using beds that will rise or stacks of pillows to elevate an arm or a leg during the recovery process. When you are elevating a leg or an arm, you shouldn’t feel a lot of discomfort. If it feels uncomfortable to prop up an injured body part, then you should avoid this treatment.
Compress the Damaged Body Part
You can wear a compression bandage or an elastic brace to help a torn tendon heal. Make sure to measure your injured knee, wrist or elbow carefully to find a brace that fits snugly but that isn’t too tight. Compression can alleviate your pain along with keeping the torn tendon in the correct position so that it will mend correctly.
Visit a Medical Specialist
If your ankle is injured, then you can experience a torn tendon. An ankle injury is serious because this part of the body is complicated with numerous tendons that are attached to muscles. When you have an ankle problem, mobility can become difficult, and if the injury takes too long to heal, then your daily life is disrupted. Experts recommend visiting an ankle doctorfor your tendon injury to have a faster recovery.
Resting during Your Recovery Process
You should avoid using the damaged body part too much while you are recovering. By sleeping more, your body’s glands will produce healing hormones that can help your torn tendon to repair faster. At the same time, as you begin to feel better, moving your leg, arm or shoulder can prevent any adhesions that can develop in your deeper tissues.
Heat and Ice Treatments for Torn Tendons
With your physician’s approval, you can use a heating pad or an ice pack on a damaged tendon. Remember that you should only use these treatments for a few minutes several times a day or night to avoid additional damage to the body’s tissues.
Cipher Pharmaceuticals Receives Health Canada Approval For Trulance® (Plecanatide)
OAKVILLE, ON, Oct. 18, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has received Health Canada approval, on October 10, 2019, for TRULANCE® (plecanatide), a Guanylate cyclase-C (GCC) agonist in the form of a once-daily tablet for the treatment of adults with irritable bowel syndrome with constipation ("IBS-C").
"We are pleased to announce TRULANCE® has achieved Health Canada approval and we are excited to be able to bring this new and effective treatment option to Canadians who suffer from this condition," said Craig Mull, Interim CEO of Cipher.
It is estimated that one in four Canadians has symptoms of constipation and an estimated 38% of Canadians report constipation within the previous 12 months1. According to IQVIA the total Canadian laxative and antispasmodic market (prescription and OTC) was valued at over CDN $200 million for the 12 months ending December 2018.
Consistent with its strategy to focus on partnering assets, Cipher is in the process of selecting a distribution partner for TRULANCE® that possesses the expertise and scale to successfully bring this novel product to market.
Cipher acquired the Canadian rights to develop, market, distribute and sell TRULANCE® from Bausch Health Companies Inc.
About Irritable Bowel Syndrome with Constipation (IBS-C)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by recurrent abdominal pain and associated with either a change in the frequency of stool, or a change in the form (appearance) of the stool. IBS can be subtyped by the predominant stool form: constipation (IBS-C), diarrhea (IBS-D) or mixed (IBS-M). Those within the IBS-C subtype experience hard or lumpy stools more than 25% of the time.
AboutTRULANCE®
TRULANCE® is a once-daily tablet approved by Health Canada for adults with IBS-C. With the exception of a single amino acid substitution for greater binding affinity, TRULANCE® is structurally identical to uroguanylin, a naturally occurring and endogenous human GI peptide. Uroguanylin activates GC-C receptors in a pH-sensitive manner primarily in the small intestine, stimulating fluid secretion and maintaining stool consistency necessary for regular bowel function.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.
Forward-Looking Statements This document includes forward-looking statements within the meaning of applicable securities laws. These forward-looking statements include, among others, statements with respect to our objectives, goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates and intentions and statements relating to Cipher's acquisition of Cardiome Pharma Corp. ("Cardiome") pursuant to which Cipher acquired the Canadian business portfolio of Cardiome, including statements in respect of the anticipated strategic and/or financial benefits of the arrangement, anticipated regulatory approvals of products and the timing thereof. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective", "hope" and "continue" (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements.
By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. We caution readers not to place undue reliance on these statements as a number of important factors, many of which are beyond our control, could cause our actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. These factors include, but are not limited to, our ability to enter into in-licensing, development, manufacturing and marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our dependency on a limited number of products; our dependency on protection from patents that will expire; integration difficulties and other risks if we acquire or in-license technologies or product candidates; reliance on third parties for the marketing of certain products; the product approval process is highly unpredictable; the timing of completion of clinical trials, regulatory submissions and regulatory approvals; reliance on third parties to manufacture our products and events outside of our control that could adversely impact the ability of our manufacturing partners to supply products to meet our demands; we may be subject to future product liability claims; unexpected product safety or efficacy concerns may arise; we generate license revenue from a limited number of distribution and supply agreements; the pharmaceutical industry is highly competitive; requirements for additional capital to fund future operations; products in Canada may be subject to pricing regulation; dependence on key managerial personnel and external collaborators; no assurance that we will receive regulatory approvals in the U.S., Canada or any other jurisdictions and current uncertainty surrounding health care regulation in the U.S.; certain of our products are subject to regulation as controlled substances; limitations on reimbursement in the healthcare industry; limited reimbursement for products by government authorities and third-party payor policies; products may not be included on list of drugs approved for use in hospitals; hospital customers may make late payments or not make any payments; various laws pertaining to health care fraud and abuse; reliance on the success of strategic investments and partnerships; the publication of negative results of clinical trials; unpredictable development goals and projected time frames; rising insurance costs; ability to enforce covenants not to compete; risks associated with the industry in which it operates; we may be unsuccessful in evaluating material risks involved in completed and future acquisitions; we may be unable to identify, acquire or integrate acquisition targets successfully; legacy risks from operations conducted in the U.S.; inability to meet covenants under our long term debt arrangement; compliance with privacy and security regulation; our policies regarding returns, allowances and chargebacks may reduce revenues; certain current and future regulations could restrict our activities; additional regulatory burden and controls over financial reporting; reliance on third parties to perform certain services; general commercial litigation, class actions, other litigation claims and regulatory actions; the difficulty for shareholders to realize in the United States upon judgments of U.S. courts predicated upon civil liability of the Company and its directors and officers who are not residents of the United States; the potential violation of intellectual property rights of third parties; our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our products; changes in U.S., Canadian or foreign patent laws; litigation in the pharmaceutical industry concerning the manufacture and supply of novel and generic versions of existing drugs; inability to protect our trademarks from infringement; shareholders may be further diluted if we issue securities to raise capital; volatility of our share price; the actions of a significant shareholder; we do not currently intend to pay dividends; our operating results may fluctuate significantly; and our debt obligations will have priority over the common shares of the Company in the event of a liquidation, dissolution or winding up.
We caution that the foregoing list of important factors that may affect future results is not exhaustive. When reviewing our forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Additional information about factors that may cause actual results to differ materially from expectations, and about material factors or assumptions applied in making forward-looking statements, may be found in the "Risk Factors" section of this MD&A and the Annual Information Form for the year ended December 31, 2018, and elsewhere in our filings with Canadian securities regulators. Except as required by Canadian securities law, we do not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf; such statements speak only as of the date made. The forward-looking statements included herein are expressly qualified in their entirety by this cautionary language.
(1) "Understanding the Prevalence and Impact of Constipation in Canada": A Special Report from the Canadian Digestive Health Foundation.
SOURCE Cipher Pharmaceuticals Inc.
Avicanna (TSX: AVCN) Announces Receipt of the First Colombian USDA Organic Certification for its Hemp Cultivation and Registration of 15 Additional Genetics
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/
TORONTO, Oct. 18, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that Santa Marta Golden Hemp S.A.S. ("SMGH"), a majority owned subsidiary of the Company, has obtained a United States Department of Agriculture ("USDA") National Organic Program ("NOP") certification from Control Union Certifications, for its hemp cultivar, and has obtained registration for an additional 15 genetic strains of cannabis.
USDA Organic Certification
Receipt of a NOP certification from the USDA for the cultivation of hemp (non-psychoactive cannabis) makes SMGH the first producer to receive this certification in Colombia. As a result, SMGH's organic cultivation practices are now validated by the USDA, which positions the Company to provide certified organic hemp derivatives for use in supplements and food products produced or shipped to the United States. The USDA protects consumers by allowing certified growers to use the USDA organic logo on products that are grown without the use of synthetic fertilizers, pesticides or herbicides. Any products intended for medical purposes coming from this organic cultivated hemp are outside of the scope of this certificate and cannot be commercialized as "organic".
Aras Azadian, the Company's Chief Executive Officer, stated, "Receiving the USDA NOP certification marks a significant milestone in our commitment to help set the highest quality standards in organic and sustainable cannabis cultivation, as we take another step forward towards becoming a global leader in the CBD industry. We expect this achievement to facilitate our growth strategy, which includes the expansion of both our plant-derived active pharmaceutical ingredients ("APIs") and bulk CBD formulations, as well as our branded lines of finished derma-cosmetics and phyto-therapeutic products into the U.S. and European markets where the USDA certification is a premium differentiator for those product categories that allow hemp to be certified as organic."
About Organic Cultivation
Dedicated to environmental preservation, SMGH will cultivate 100% sun-grown USDA certified organic hemp. Implementing Good Agricultural and Collection Practices and promoting a living soil system, SMGH's plants will grow healthy. The use of chemical pesticides and herbicides is harmful for the consumer, the plant, and mostly the environment. Plants grown under the pressure of conventional practices don't develop to produce their full potential of nutrients and benefits. Chemicals used in conventional agriculture are responsible for poisoning water sources, damaging the soil and diminishing its ability to sequester carbon dioxide which is a major cause for global warming. SMGH strives to maintain its soils free from synthetic compounds as a compromise to our planet.
Registration of Additional Genetics
On October 18, 2019, Avicanna received confirmation that SMGH has obtained registrations for 11 strains of psychoactive cannabis and 4 strains of non-psychoactive cannabis. Following such registration, SMGH has a total of 14 registered strains of psychoactive cannabis and 5 registered strains of non-psychoactive cannabis. SMGH, can commence production of products containing each strain of non-psychoactive cannabis that has been registered and, upon receipt of a quota with respect to each registered psychoactive strain, SMGH will be able to commence production of products containing each strain of its registered psychoactive cannabis strains. In addition, such registration enables SMGH to market seeds of such registered genetics and export propagation material (upon receipt of necessary approvals).
"Achieving this additional registration not only expands Avicanna's genetic bank for commercial purposes but also reflects our commitment to work with a wide range of varieties that provide a new range of cannabinoids for our research and development projects. This registration will also enhance our capacity to continue improving and stabilizing high performance genetics as part of our breeding program," said Avicanna's Chief Agricultural Officer, Lucas Nosiglia.
About Avicanna
Avicanna is an Ontario corporation focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.
Avicanna's two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna's cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).
Avicanna's research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna's scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.
Avicanna's research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.
Stay Connected
For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email info@avicanna.com.
Cautionary Note Regarding Forward-Looking Information and Statements
Certain information in this press release contains forward-looking statements. Such statements include but are not limited to the ability of the Company to use its organic hemp in supplements and food products, the expectation that the receipt of the NOP certification will allow the Company to accelerate growth, that SMGH will cultivate 100% sun-grown USDA organic hemp and that SMGH will be able to commence production of its registered psychoactive strains of cannabis. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict, including the risk factors set out under the heading "Risk Factors" in the Company's long form final prospectus dated July 8, 2019. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements, unless and until required by securities laws applicable to the Company.
SOURCE Avicanna Inc.
Garamendi and Hartzler Introduce Bill to Protect Service Members from Chinese-Controlled Generic Pharmaceutical Industry
Washington, DC—Today, Congressman John Garamendi (D-CA), Chairman of the Readiness Subcommittee within the House Armed Services Committee, and Congresswoman Vicky Hartzler (R-MO), Ranking Member of the Tactical Air and Land Forces Subcommittee within the House Armed Services Committee, introduced the "Pharmaceutical Independence Long-Term Readiness Reform Act" (H.R. 4710).
The legislation requires the Department of Defense to identify the vulnerabilities faced by our country’s dependence on Chinese pharmaceuticals, and to only purchase American-made raw materials, medicines, and vaccines for the military.
“Right now, China has the ability to attack the United States without firing a single shot by poisoning our servicemembers’ medicines or cutting off their supply.” Garamendi said. “The Chinese government is the principal developer of generic prescriptions, which account for approximately 90 percent of pharmaceuticals. China’s chokehold on the global pharmaceutical market leaves our servicemembers and our nation vulnerable to attack. We need to reinvigorate the United States industrial base to produce generic medicines and antibiotics domestically. Doing so will create thousands of new middle-class jobs and make our country safer. I appreciate Congresswoman Hartzler’s partnership in our effort to resolve this issue.”
“Put simply, China having control over the production of our military’s medicine poses a grave national security threat. Not only does it open the possibility of them deliberately manipulating our servicemember’s medical regimens and causing physical harm, but the Chinese government’s lack of proper oversight and regulatory standards on prescription drugs is also deeply alarming to me. We need to ensure that our military’s medicine is American-made,” Hartzler said.
The full text of the "Pharmaceutical Independence Long-Term Readiness Reform Act" (H.R. 4710) can be viewed here.
Coaster Introduces the Venture 500 ALEX to Support Pediatric Cancer Research
First of Kind “Mobile Lemonade Stand” Will Be Available for Rental and Purchase
[SAN FRANCISCO, CA] Today, Coaster Cycles unveiled a new model – the Coaster Venture 500 ALEX - inspired by its partnership with Alex’s Lemonade Stand Foundation (ALSF). This new model will be a key part of Coaster’s support to ALSF, a featured community partner of the Company. The limited edition mobile lemonade stand will operate at select locations in the Bay Area with all proceeds benefiting the Foundation.
Coaster manufactures and operates eco-friendly mobility products that provide transportation, delivery, and branding services for a range of clients, including Fortune 500s, governments, universities, events, and retailers. Coaster will offer the Coaster Venture 500 ALEX for direct purchase with proceeds benefiting ALSF.
Proudly made in the USA, Coaster builds all of its vehicles at its 24,000 sq. ft. facility in Missoula, MT. The Venture series offers a leading solution for food and beverage companies such as Starbucks, Aramark, Constellation, Pepsi, and many more. The Venture – and all Coaster Cycles - can operate in the bike lane, does not require a driver’ license, and helps reduce congestion and pollution.
“In building a partnership with ALSF, the product and mission alignment, potential for high scale impact, and our personal passion for the cause made it a perfect fit.” said Ben Morris, Founder and CEO of Coaster.
Our hope is that in making the Coaster Venture 500 ALEX available for purchase, and eventually rental, it will become a staple of concessions at concerts, sporting events, universities, corporate campuses and beyond, all in support of the Foundation.”
“We welcome the opportunity to work closely with Coaster. Like ALSF, Coaster is committed to providing resources for finding the best research and better, less toxic treatments for children fighting cancer,” said Liz Scott, co-executive director of ALSF and Alex’s mom.
In addition, as a Featured Community Partner, Coaster will support ALSF through a variety of charitable integrated programs. The company will make a donation that will help fund impactful research and family resources ($20) for every Coaster sold, offer clients the opportunity to add a donation to ALSF at checkout, organize Coaster service days in support of ALSF, and raise awareness of ALSF activities and fundraising initiatives.
About Alex's Lemonade Stand Foundation (ALSF)
Alex's Lemonade Stand Foundation (ALSF) emerged from the front yard lemonade stand of 4-year-old Alexandra “Alex” Scott, who was fighting cancer and wanted to raise money to find cures for all children with cancer. Her spirit and determination inspired others to support her cause, and when she passed away at the age of 8, she had raised $1 million. Since then, the Foundation bearing her name has evolved into a national fundraising movement. Today, ALSF is one of the leading funders of pediatric cancer research in the U.S. and Canada raising more than $175 million so far, funding nearly 1,000 research projects and providing programs to families affected by childhood cancer. For more information, visit AlexsLemonade.org.
About Coaster Cycles
Coaster Cycles' mission is to inspire communities and brands to move, connect and deliver with the world around them. Coaster manufactures and operates eco-friendly mobility products that provide transportation, delivery, and branding services for a range of clients, including Fortune 500s, governments, universities, events, and retailers. Proudly made in the USA, Coaster manufactures in a 24,000 sq. ft. facility in Missoula, MT. The company also operates fleets in Boston, New York and San Francisco and activates ad campaigns nationally.
Take It Slow: How to Get Back into Working out after a Long Break
For healthy adults, working out at least 20 minutes a day is highly recommended. For those of us with busy schedules, exercise can become less of a priority or even nonexistent overtime. Getting back into a workout regimen, if done properly, is possible. Taking proper precautions will get you back into your workout routine.
Seek Professional Advice Prior to Starting Your Regimen
Before starting your workout regimen, seek a healthcare professional and get a proper evaluation. Understanding your initial health condition will help determine the routine you should follow and if there are any issues, the physician can remedy them before beginning.
Pace Yourself
Jumping back into your original workout regimen can be injurious. Muscle deterioration comes with taking breaks from exercising, so starting with low-intensity workouts and gradually increasing the intensity will give the best results. Also, be comfortable with the intensity you can handle initially. If you can only tolerate one or two days per week, that is okay. Feeling obligated to doing more than your body can handle is counterproductive to achieving your workout goals.
Use Proper Warm-Ups and Cool-Downs When Exercising
Before working out, warm ups are necessary to get your body ready for the regimen’s intensity. Stretching is a great way to warm up. It is also important to stretch when cooling down after a workout, which brings your heart rate back down to its original rest rate. Your body also experiences delayed onset muscle soreness (DOMS) if you haven’t worked out consistently. Incorporating stretching into warm-up and cool-down routines will eliminate some of this soreness.
Be Sure to Rest
Resting is just as important to muscle restoration as your workout regimen. When your body is tired or sore, take heed and refrain from putting further stress on your muscles. Be sure to get adequate sleep also; exercising burns lots of calories, causing fatigue. Going to sleep earlier or taking a nap after a workout will help rebuild muscles and relieve soreness. Also, try working in massages whenever possible. If you suffer any severe soreness or joint pain, seek necessary healthcare, including knee pain treatmentor physical therapy.Getting back into working out is great, when done safely. The goal of getting in shape should be to maintain your health, so practicing healthy habits like resting, proper pace, and getting professional health evaluations are key to coming back to your exercising routine. Use self-awareness and ease into regimens to reach you
ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tau
Data show antibody candidates bind toxic forms of tau and inhibit its propagation in a cellular model
TORONTO and CAMBRIDGE, MA, Oct. 17, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, continues to further develop antibody candidates that have shown selectivity for the toxic forms of tau. New pre-clinical data show that these antibody candidates can block the spread of pathogenic tau aggregate formation in a cellular model. Continued advancement of ProMIS' dual approach for Alzheimer's disease, which also includes antibody PMN310 targeting the toxic oligomers of amyloid-beta, aligns with research indicating that both misfolded proteins play a major role in disease progression and represent highly validated targets for therapy.
ProMIS announced its tau program in May 2019 when it identified several novel antibody candidates that preferentially bind toxic forms of tau. Pre-clinical data now show that these candidates can block the formation of pathogenic tau aggregates in a cellular model. ProMIS leveraged its proprietary drug discovery and development platform to identify conformational epitopes on misfolded tau and generate, evaluate and advance tau antibody candidates, demonstrating the platform's capacity for producing high-quality antibody candidates rapidly and cost-effectively.
"The misfolded, toxic forms of tau and amyloid-beta are the two most validated targets in Alzheimer's therapy development," said Elliot Goldstein, MD, President and CEO of ProMIS Neurosciences. "While addressing Alzheimer's will require a multifactorial approach, selective targeting of misfolded, toxic forms of both tau and amyloid-beta remains one of the most promising therapeutic strategies for Alzheimer's disease. We will continue to strengthen our programs, offering the critical one-two punch needed for a disease-modifying therapy, while simultaneously seeking ways to leverage emerging biomarkers to improve the success and speed of future clinical development."
To learn more about the search for therapies for Alzheimer's, Parkinson's and other neurodegenerative diseases, listen to the podcast, Saving Minds, at iTunes or Spotify.
About ProMIS Neurosciences ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines – ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE ProMIS Neurosciences Inc.
Is a Herpes Vaccine Finally Here? By Dr. Eddie Fatakhov MD
A vaccine for genital herpes has been in the works for close to 100 years. The majority of these prospective vaccines have failed, with some even making it to the human testing phase. Genital Herpes, or Herpes Simplex Virus-2 (HSV-2), is spread by vaginal, anal or oral sex, and is a more serious condition than common cold sores, or Herpes Simplex Virus-1 (HSV-1).
Genital herpes is common in the United States according to the Centers for Disease Control and Prevention that estimates more than 1 in 6 people aged 14 to 49 have genital herpes, with as many as 90% of these people not even knowing they have herpes due to lack of symptoms. The concerning issue with genital herpes is that the virus can be spread by people who have no symptoms and essentially, do not know they have it.
With so many sexually transmitted diseases (STDs) that seem to be common knowledge in this day and age, what is important to note about genital herpes is that there is no known cure. Medications are available to reduce viral outbreaks and lessen the likelihood of spreading the virus to a partner, but no medication to make it disappear. Carrying genital herpes also makes you 3 to 4 more times at risk for other viruses such as HIV. The open sores caused by the herpes virus provide an entryway for HIV to enter the body. Genital herpes is also a little “discriminatory” when it comes to gender and ethnicity. Twice as many women have the virus than men. Male-to-female transmission of herpes is easier than female-to-male transmission. Genital herpes is also more common among non-Hispanic blacks than non-Hispanic whites. The trended research shows that economic differences play a role in the spread of genital herpes.
While genital herpes is widespread, it is not the most common STD. Human papillomavirus (HPV) has the dubious distinction as the most common STD, but it now has a vaccine. Genital herpes comes in second place, making the development of a vaccine imperative. University of Pennsylvania scientists may be closer than ever. Their most recent published results show that immunization not only totally prevented genital herpes in mice and guinea pigs, but it very effectively kept the virus from retreating into nerve roots. The nerve roots are where the infection can hide and remain symptomless yet still transmitted. These mice and guinea pigs developed no clinical infection (with symptoms), and no subclinical infection that allows for spreading without symptoms. The next step is to get approval from the FDA to begin human trials.
To those who question the importance of such a vaccine, or find yourself saying “just protect yourself, use condoms, get tested, know your partners, etc.”, understand genital herpes can carry much bigger risks than the potential outbreak of occasional painful sores on your body. If the infection is passed to an infant (which can happen before, during, or after birth), it can cause severe disability or even death from complications such as meningitis. This fact alone greatly supports the need for vaccination.
Although this is exciting news in the medical field, we would still be quite some time away from a final product. Clinical trials could take 8 years or longer. The long-term vision would be teenagers receiving an HSV-2 Vaccine alongside the HPV vaccine, which is already protecting them from cervical, throat and mouth cancer. We have made it a reality that we will now see future populations with a significantly lower prevalence of HPV, resulting in less cancer. While HSV-2 is a virus with no cure, a vaccine that could prevent someone from ever getting it to begin with, while also potentially reducing HIV transmission rates. This would be ground-breaking for our future generations.
In Search of the Perfect Strain: Top Cultivator in California’s “Wine Country” of Weed Shares Generational Wisdom Behind One Family’s Decades-Long Pursuit of the Perfect Toke
Committed to purity and sustainability, Autumn Brands’ Head Grower talks sixth-generation Dutch farming techniques and the challenges of spearheading a “no-spray” operation
LOS ANGELES, California – (October 17th, 2019): Backed by decades of hard-won sustainable farming expertise, 50% woman-owned Autumn Brands stands out as a sixth-generation, family-run operation with a health-centered holistic focus and refreshingly artisanal approach. Running a large-scale cannabis operation presents a variety of challenges for any commercial grower. Every aspect of cultivation requires strategic precision, from selecting the hardiest strains to keeping up with increasing demand for product. In a notoriously competitive market, many sellers rely on harsh chemicals and pesticides to speed the growth process and ensure a strong final product. Under the watchful eye of Head Grower Johnny Brand, Autumn Brands far surpasses federal and state regulatory standards, offering powerfully potent strains of clean, pesticide-free cannabis from a name customers trust for quality and consistency.
“As no-spray cannabis farmers, we have few of the tools traditional growers use to battle things like mildew and mold,” explains Johnny Brand of Autumn Brands’ rigorous, hands-on approach. Once he establishes that a particular strain is not hypersensitive to the ravages of moisture, he tests 10 plants and observes their unique growth patterns through three distinct stages: first, he notes how easily clones take root and how quickly they grow. Next, Brand looks for plants that swell quickly, producing strong trichomes (the sticky resin glands responsible for their THC, CBD, and other cannabinoid content) and terpenes (which give each strain its unique flavor and aroma). Finally, post-harvest, the plants are dried, hand-trimmed, and lab-tested to verify THC and CBD levels, as well as other beneficial cannabinoids.
“The full process takes around 6 months, and I’m constantly searching for new strains to test and grow,” says Brand. Fortunately, several family-owned greenhouses give the company a unique edge: the freedom to grow and test product year-round in conjunction with the weather. “Indoor grows can operate year-round, regardless of the weather. Outdoor grows can only cultivate in warmer seasons,” he explains. “We’ve grown in the same greenhouses for more than 27 years, as hard-won knowledge from my grandpa and my dad passed down to me. My favorite part of our approach is the ability to work with the seasons; some plants change color and growth speed depending on the weather - which makes the testing process especially challenging - but it’s also what keeps me engaged in the process.”
Autumn Brands brings an uncompromising work ethic, informed by generations of family farming, to the task of producing hand-selected, sun-grown buds - each hang-dried, hand-trimmed, and cured to preserve maximum potency and full healing benefits. Overseeing every stage of their no-spray growth process, Johnny Brand and his expert team deliver sustainably sourced, farm-to-consumer cannabis to a blossoming health and wellness market. Visit www.AutumnBrands.com to learn more and discover their full selection of premium flower, pre-rolls, and pre-filled cartridges. Follow on Instagram @AutumnBrands for the latest product releases and updates.
About Autumn Brands:
Autumn Brands is a licensed California cannabis cultivator dedicated to the synergy of health and wellness. The Autumn Brands’ family farm started in Holland more than a century ago, and today, sixth-generation farmers apply the same expertise garnered in growing the world’s finest tulips to producing pure and potent strains of cannabis in sunny, coastal Santa Barbara County. Autumn Brands is proud to be 50 percent woman-owned, free of pesticides and other harmful chemicals. For more information, visit www.autumnbrands.com or email leighanne@anderson-pr.com.
